Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 2
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apoli…
Proteinuric Kidney Disease
Estimated
~$10 – $8,750
Vertex Pharmaceuticals IncorporatedNCT05312879
Phase 2
PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minima…
Proteinuric Kidney Diseases
Estimated
~$10 – $7,500
Boehringer IngelheimNCT07355296
Phase 1
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer…
Proteinuric Renal DiseaseProteinuric Kidney DiseaseProteinuria+1 more
Estimated
~$10 – $6,250
Brigham and Women's HospitalNCT07224776
Phase 2
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Proteinuric Kidney Disease
Estimated
~$10 – $8,750
Maze TherapeuticsNCT06830629